Text Size

Copeptin in Aortic Valve Replacement (CARE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Deutsches Herzzentrum Muenchen
ClinicalTrials.gov Identifier:
NCT01648647
First received: July 20, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted
  Purpose

Copeptin is accepted as a marker of stress. We want to evaluate the preoperative and early postoperative copeptin leavens in patients undergoing different aortic valve procedures


Condition
Copeptin in Patients Undergoing Aortic Valve Replacement

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: GE DHM-AN-OR-2012/01

Further study details as provided by Deutsches Herzzentrum Muenchen:

Enrollment: 50
Study Start Date: May 2012
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients scheduled for surgical or transcatheter aortic valve replacement

Criteria

Inclusion Criteria:

  • Patients undergoing surgical aortic valve replacment
  • Patients undergoing transcatheter aortic valve replacment

Exclusion Criteria:

  • denial by patient
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01648647

Locations
Germany
Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München
Munich, Bavaria, Germany, D80636
Sponsors and Collaborators
Deutsches Herzzentrum Muenchen
  More Information

No publications provided

Responsible Party: Deutsches Herzzentrum Muenchen
ClinicalTrials.gov Identifier: NCT01648647     History of Changes
Other Study ID Numbers: GE DHM-AN-OR-2012/01
Study First Received: July 20, 2012
Last Updated: July 20, 2012
Health Authority: Germany: Ethikkommission der Fakultät für Medizin

ClinicalTrials.gov processed this record on May 23, 2013